company background image
688185 logo

CanSino Biologics SHSE:688185 Stock Report

Last Price

CN¥68.29

Market Cap

CN¥12.2b

7D

0.4%

1Y

-11.5%

Updated

09 Dec, 2024

Data

Company Financials +

CanSino Biologics Inc.

SHSE:688185 Stock Report

Market Cap: CN¥12.2b

688185 Stock Overview

Develops, manufactures, and commercializes vaccines in the People’s Republic of China. More details

688185 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

CanSino Biologics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CanSino Biologics
Historical stock prices
Current Share PriceHK$68.29
52 Week HighHK$85.58
52 Week LowHK$37.12
Beta0.46
11 Month Change11.11%
3 Month Change74.30%
1 Year Change-11.47%
33 Year Change-75.35%
5 Year Changen/a
Change since IPO-82.63%

Recent News & Updates

Recent updates

Shareholder Returns

688185CN BiotechsCN Market
7D0.4%1.1%2.2%
1Y-11.5%-16.9%10.2%

Return vs Industry: 688185 exceeded the CN Biotechs industry which returned -16.9% over the past year.

Return vs Market: 688185 underperformed the CN Market which returned 10.2% over the past year.

Price Volatility

Is 688185's price volatile compared to industry and market?
688185 volatility
688185 Average Weekly Movement12.2%
Biotechs Industry Average Movement8.9%
Market Average Movement8.5%
10% most volatile stocks in CN Market12.7%
10% least volatile stocks in CN Market5.7%

Stable Share Price: 688185's share price has been volatile over the past 3 months compared to the CN market.

Volatility Over Time: 688185's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of CN stocks.

About the Company

FoundedEmployeesCEOWebsite
20091,149Xuefeng Yuwww.cansinotech.com

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.

CanSino Biologics Inc. Fundamentals Summary

How do CanSino Biologics's earnings and revenue compare to its market cap?
688185 fundamental statistics
Market capCN¥12.17b
Earnings (TTM)-CN¥720.11m
Revenue (TTM)CN¥748.53m

10.2x

P/S Ratio

-10.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688185 income statement (TTM)
RevenueCN¥748.53m
Cost of RevenueCN¥774.40m
Gross Profit-CN¥25.87m
Other ExpensesCN¥694.25m
Earnings-CN¥720.11m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.91
Gross Margin-3.46%
Net Profit Margin-96.20%
Debt/Equity Ratio41.3%

How did 688185 perform over the long term?

See historical performance and comparison